Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: Validation and application

Kim Keil, Jill Hochreitter, Robin DiFrancesco, Barry S. Zingman, Richard C. Reichman, Margaret A. Fischl, Barbara Gripshover, Gene D. Morse

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Atazanavir (ATV) is a widely used human immunodeficiency virus (HIV)-1 protease inhibitor (PI) that, like other approved PIs, has been considered as a candidate for therapeutic drug monitoring (TDM). To provide ATV assay results that can be applied to patient management through TDM, the assay would need to perform in a manner consistent with Clinical Laboratory Improvement Amendments (CLIA) standards. To quantitate ATV concentrations in human plasma, the authors added ATV to a previously published reversed-phase high-performance liquid chromatography (HPLC) method from their laboratory. Detection was effected with use of a photodiode-array detector (PDA) collecting spectra at 248 nm. This method allows for detection of ATV to a lower limit of quantitation of 0.05 μg/mL, with an intra-assay coefficient of variation (CV%) of 8.9% or less over 5 days of testing and an interassay CV% ranging from 1.4 to 6.4%. The assay has met passing requirements for interlaboratory proficiency testing for 2 years nationally and internationally, with accuracy within ±15% over all test samples. During 2 years, more than 100 batches of analyses have been performed and have proved the method is rugged, specific, and accurate. This assay method is currently used in the authors' clinical research program in TDM.

Original languageEnglish (US)
Pages (from-to)103-109
Number of pages7
JournalTherapeutic Drug Monitoring
Volume29
Issue number1
DOIs
StatePublished - Feb 2007

Fingerprint

Liquid chromatography
Protease Inhibitors
Liquid Chromatography
Assays
Drug Monitoring
Monitoring
Pharmaceutical Preparations
Clinical laboratories
Plasma (human)
High performance liquid chromatography
Testing
Reverse-Phase Chromatography
Photodiodes
Viruses
HIV-1
High Pressure Liquid Chromatography
Atazanavir Sulfate
Detectors
Research

Keywords

  • Antiretrovirals
  • Atazanavir
  • Liquid chromatography
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors : Validation and application. / Keil, Kim; Hochreitter, Jill; DiFrancesco, Robin; Zingman, Barry S.; Reichman, Richard C.; Fischl, Margaret A.; Gripshover, Barbara; Morse, Gene D.

In: Therapeutic Drug Monitoring, Vol. 29, No. 1, 02.2007, p. 103-109.

Research output: Contribution to journalArticle

Keil, Kim ; Hochreitter, Jill ; DiFrancesco, Robin ; Zingman, Barry S. ; Reichman, Richard C. ; Fischl, Margaret A. ; Gripshover, Barbara ; Morse, Gene D. / Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors : Validation and application. In: Therapeutic Drug Monitoring. 2007 ; Vol. 29, No. 1. pp. 103-109.
@article{d1656eb0a80a4fb589c77ed3a3671b81,
title = "Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: Validation and application",
abstract = "Atazanavir (ATV) is a widely used human immunodeficiency virus (HIV)-1 protease inhibitor (PI) that, like other approved PIs, has been considered as a candidate for therapeutic drug monitoring (TDM). To provide ATV assay results that can be applied to patient management through TDM, the assay would need to perform in a manner consistent with Clinical Laboratory Improvement Amendments (CLIA) standards. To quantitate ATV concentrations in human plasma, the authors added ATV to a previously published reversed-phase high-performance liquid chromatography (HPLC) method from their laboratory. Detection was effected with use of a photodiode-array detector (PDA) collecting spectra at 248 nm. This method allows for detection of ATV to a lower limit of quantitation of 0.05 μg/mL, with an intra-assay coefficient of variation (CV{\%}) of 8.9{\%} or less over 5 days of testing and an interassay CV{\%} ranging from 1.4 to 6.4{\%}. The assay has met passing requirements for interlaboratory proficiency testing for 2 years nationally and internationally, with accuracy within ±15{\%} over all test samples. During 2 years, more than 100 batches of analyses have been performed and have proved the method is rugged, specific, and accurate. This assay method is currently used in the authors' clinical research program in TDM.",
keywords = "Antiretrovirals, Atazanavir, Liquid chromatography, Therapeutic drug monitoring",
author = "Kim Keil and Jill Hochreitter and Robin DiFrancesco and Zingman, {Barry S.} and Reichman, {Richard C.} and Fischl, {Margaret A.} and Barbara Gripshover and Morse, {Gene D.}",
year = "2007",
month = "2",
doi = "10.1097/FTD.0b013e3180318ef3",
language = "English (US)",
volume = "29",
pages = "103--109",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors

T2 - Validation and application

AU - Keil, Kim

AU - Hochreitter, Jill

AU - DiFrancesco, Robin

AU - Zingman, Barry S.

AU - Reichman, Richard C.

AU - Fischl, Margaret A.

AU - Gripshover, Barbara

AU - Morse, Gene D.

PY - 2007/2

Y1 - 2007/2

N2 - Atazanavir (ATV) is a widely used human immunodeficiency virus (HIV)-1 protease inhibitor (PI) that, like other approved PIs, has been considered as a candidate for therapeutic drug monitoring (TDM). To provide ATV assay results that can be applied to patient management through TDM, the assay would need to perform in a manner consistent with Clinical Laboratory Improvement Amendments (CLIA) standards. To quantitate ATV concentrations in human plasma, the authors added ATV to a previously published reversed-phase high-performance liquid chromatography (HPLC) method from their laboratory. Detection was effected with use of a photodiode-array detector (PDA) collecting spectra at 248 nm. This method allows for detection of ATV to a lower limit of quantitation of 0.05 μg/mL, with an intra-assay coefficient of variation (CV%) of 8.9% or less over 5 days of testing and an interassay CV% ranging from 1.4 to 6.4%. The assay has met passing requirements for interlaboratory proficiency testing for 2 years nationally and internationally, with accuracy within ±15% over all test samples. During 2 years, more than 100 batches of analyses have been performed and have proved the method is rugged, specific, and accurate. This assay method is currently used in the authors' clinical research program in TDM.

AB - Atazanavir (ATV) is a widely used human immunodeficiency virus (HIV)-1 protease inhibitor (PI) that, like other approved PIs, has been considered as a candidate for therapeutic drug monitoring (TDM). To provide ATV assay results that can be applied to patient management through TDM, the assay would need to perform in a manner consistent with Clinical Laboratory Improvement Amendments (CLIA) standards. To quantitate ATV concentrations in human plasma, the authors added ATV to a previously published reversed-phase high-performance liquid chromatography (HPLC) method from their laboratory. Detection was effected with use of a photodiode-array detector (PDA) collecting spectra at 248 nm. This method allows for detection of ATV to a lower limit of quantitation of 0.05 μg/mL, with an intra-assay coefficient of variation (CV%) of 8.9% or less over 5 days of testing and an interassay CV% ranging from 1.4 to 6.4%. The assay has met passing requirements for interlaboratory proficiency testing for 2 years nationally and internationally, with accuracy within ±15% over all test samples. During 2 years, more than 100 batches of analyses have been performed and have proved the method is rugged, specific, and accurate. This assay method is currently used in the authors' clinical research program in TDM.

KW - Antiretrovirals

KW - Atazanavir

KW - Liquid chromatography

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=33847107702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847107702&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e3180318ef3

DO - 10.1097/FTD.0b013e3180318ef3

M3 - Article

C2 - 17304157

AN - SCOPUS:33847107702

VL - 29

SP - 103

EP - 109

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -